NCT06350981View on ClinicalTrials.gov

Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

March 1, 2026

Conditions
Back PainSurgery-ComplicationsNarcotic UsePhysical StressPost Operative Pain
Interventions
DRUG

Exparel

20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine

DRUG

Bupivacain

Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL

Trial Locations (1)

33607

Foundation for Orthopaedic Research and Education, Tampa

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Foundation for Orthopaedic Research and Education

OTHER